Skip to content
About Us
Management
History
Our Focus Area
Innovative Drugs
Pipelines
SB01&02
SB03
SB04
SB05
Ophthalmic Diagnostic Device
History
FloM-S
epiCam C
epiCam M
epiCam V
Media
News
Events
Knowledge
Investors
Financial Reports
Quarterly Reports
Financial Analysis
Financial Statements
Shareholder Information
Shareholder Structure
Shareholder Meeting
Partnering
Contact Us
English
Chinese (Traditional)
Search for:
About Us
Management
History
Our Focus Area
Innovative Drugs
Pipelines
SB01&02
SB03
SB04
SB05
Ophthalmic Diagnostic Device
History
FloM-S
epiCam C
epiCam M
epiCam V
Media
News
Events
Knowledge
Investors
Financial Reports
Quarterly Reports
Financial Analysis
Financial Statements
Shareholder Information
Shareholder Structure
Shareholder Meeting
Partnering
Contact Us
English
Chinese (Traditional)
Search for:
About Us
Management
History
Our Focus Area
Innovative Drugs
Pipelines
SB01&02
SB03
SB04
SB05
Ophthalmic Diagnostic Device
History
FloM-S
epiCam C
epiCam M
epiCam V
Media
News
Events
Knowledge
Investors
Financial Reports
Quarterly Reports
Financial Analysis
Financial Statements
Shareholder Information
Shareholder Structure
Shareholder Meeting
Partnering
Contact Us
English
Chinese (Traditional)
Search for:
Loading...
Innovative Drugs
新藥開發
Innovative Drugs
Home
/
Our Focus Area
/
SB05
SB05
Merissa
2018-11-30T18:06:20+08:00
Innovative Drugs
Pipelines
SB01&02
SB03
SB04
SB05
SB05-EndoTAG-1
PC
TNBC
Ophthalmic Diagnostic Device
Ophthalmic Diagnostic Device
Innovation
FloM-S
epiCam
epiCam C
epiCam M
epiCam V
EndoTAG
®
Positively Charged Liposomal Platform Technology for Anti-Cancer Drugs
